PBL will grant Dicerna a world-wide, non-exclusive license to the Baulcombe patents (U.S. Patent Nos. 8,097,710; 8,258,285; 8,299,235 and 8,263,569) for use in the field of human therapeutics. Financial terms were not disclosed.
“We are pleased to add the Baulcombe patents to our expanding intellectual property portfolio,” said Douglas M. Fambrough, CEO of Dicerna. “We have continued to innovate and advance our DsiRNA and EnCore technologies, allowing us to develop innovative programs against previously undruggable targets. Dicerna’s programs, along with those of our partners, means we are moving forward on multiple fronts to bring new options to patients via well-known and powerful mechanisms.”
PBL’s Managing Director, Dr. Jan Chojecki, stated, “We are delighted to add Dicerna as our partner in the development of RNAi therapeutics. Dicerna is currently advancing an exciting RNAi-based therapeutic oncology candidate into the development stage. This agreement further endorses the strength of our patent estate in the RNAi field and we look forward to working with other partners in therapeutic applications, as well as in research reagents, diagnostics and of course agricultural applications of this pivotal technology.”